Accession Number : ADA266633


Title :   A Review of the Efficacy of 7.5% NaCl/6% Dextran-70 (HSD) in Experimental Animals and Humans


Descriptive Note : Institute rept.


Corporate Author : LETTERMAN ARMY INST OF RESEARCH PRESIDIO OF SAN FRANCISCO CA


Personal Author(s) : Dubick, M A ; Wade, C E


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/a266633.pdf


Report Date : Jan 1993


Pagination or Media Count : 31


Abstract : Recent years have seen a renewed interest in the use of hypertonic- hyperoncotic solutions as plasma volume expanders for the treatment of hemorrhagic hypotension. In particular, a number of studies in experimental animals have addressed the efficacy and safety of small volume infusions of 7.5% NaCl/6% Dextran-70 (HSD). Employing models of fixed volume or fixed pressure hemorrhage, HSD has improved survival, and reversed many of the hemodynamic, hormonal, and metabolic abnormalities associated with hemorrhagic shock. In the few human field trials completed to date, HSD has been shown to be potentially beneficial in hypotensive trauma patients who require surgery or have concomitant head injury. Extensive toxicological evaluations and lack of reports of adverse effects in the human trials indicate that, at the proposed therapeutic dose of 4 ml/kg, HSD should present little risk.


Descriptors :   *THERAPY , *BLOOD VOLUME , *HEMORRHAGIC SHOCK , HUMANS , DEXTRAN , PROTEINS , MILITARY MEDICINE , WOUNDS AND INJURIES , SODIUM CHLORIDE , HEAD(ANATOMY) , TRAUMA , HYPOTENSION , HYPERTONIC , INFUSIONS , HEMORRHAGE , RESUSCITATION , LABORATORY ANIMALS , BLOOD PLASMA , TOXICOLOGY , ABNORMALITIES , SURGERY , PATIENTS , ANIMALS , MILITARY RESEARCH , PRESSURE , SAFETY


Subject Categories : Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE